Compugen Ltd. (NASDAQ:CGEN) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET

Company Participants

Yvonne Naughton - Head, Investor Relations and Corporate Communications

Anat Cohen-Dayag - President and Chief Executive Officer

Henry Adewoye - Chief Medical Officer

Eran Ophir - Senior Vice President, Research and Drug Discovery

Alberto Sessa - Chief Financial Officer

Conference Call Participants

Stephen Willey - Stifel

Mark Breidenbach - Oppenheimer

Reni Benjamin - JMP Securities

Daina Graybosch - SVB Securities

Tony Butler - ROTH Capital

Operator

Ladies and gentlemen, thank you for joining us today. Welcome to Compugen’s Third Quarter 2022 Results Conference Call. At this time, all participants are in a listen-only mode. An audio webcast of this call is available in the Investors section of Compugen’s website, www.cgen.com. As a reminder, today’s call is being recorded. I would now like to introduce Yvonne Naughton, Head of Investor Relations and Corporate Communications. Yvonne. Please go ahead.

Yvonne Naughton

Thank you, Jamie and thank you all for joining us on the call today. Joining me from Cumpogen are Dr. Anat Cohen-Dayag, President and Chief Executive Officer; Dr. Henry Adewoye, Chief Medical Officer; Dr. Eran Ophir, Senior Vice President Research and Drug Discovery; and Alberto Sessa, Chief Financial Officer.

Before we begin, we would like to remind you that during this call, the company may make projections or forward-looking statements regarding future events, business outlook, development efforts and their potential outcome, the company’s discovery platform, anticipated progress and plans, results and timelines for our programs, financial and accounting related matters as well as statements regarding our cash businesses. We wish to caution you that such statements reflect only the company’s current beliefs, expectations and assumptions, but actual results, performance or achievements of the company may differ materially. These statements are subject to known and unknown risks and uncertainties and we refer you to the SEC filings for more details on these risks, including the company’s most recent annual report on Form 20-F, filed with the SEC on February 28, 2022. The company undertakes no obligation to update projections and forward-looking statements in the future.

With that, I now turn over to Anat.

Anat Cohen-Dayag

Thank you, Yvonne. Good morning and good afternoon, everyone and welcome to our third quarter 2022 update, fresh after a great Citi Conference in Boston last week, where we had two oral presentations.

In the first 9 months of the year, we have continued to execute and meet our guidance. We presented clinical data from the MSS-CRC expansion cohort at SITC last week. And in 3 weeks’ time, we will present clinical data from the two ovarian expansion cohorts at ESMO-IO. During our first oral presentation at SITC, Dr. Michael Overman from MD Anderson presented encouraging overall response rate following treatment with COM701 in combination with nivolumab in heavily pre-treated metastatic MSS-CRC patients, a hard-to-treat tumor type, typically not responsive to immunotherapy. Over 70% of the patients from this study has liver metastasis, typical of this patient population who are resistant to treatment. Responses in these patients with liver mass, is a key differentiator for COM701 and the unique achievement.